牛牛AI助理已提取核心訊息
Eli Lilly and Company (Lilly) announced a series of significant achievements and strategic decisions in its 2023 Annual Meeting of Shareholders notice. The company reported regulatory approvals for new medicines, including Omvoh for ulcerative colitis, Jaypirca for MCL or CCL, and Zepbound for obesity. Lilly also highlighted results from the Trailblazer-ALZ 2 study indicating a slowdown in Alzheimer's disease progression. The company delivered strong shareholder returns through share price appreciation and dividends and donated over $4 billion in medicines to charitable organizations. Lilly's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030. The company engaged with investors on topics like drug pricing, global product access, and environmental, social, and governance issues. Management proposals at the 2024 annual meeting will include eliminating the classified board structure and supermajority voting requirements in the articles of incorporation. The 2024 Annual Meeting of Shareholders will be held virtually on May 6, 2024, at 8:30 a.m. EDT.
Eli Lilly and Company (Lilly) announced a series of significant achievements and strategic decisions in its 2023 Annual Meeting of Shareholders notice. The company reported regulatory approvals for new medicines, including Omvoh for ulcerative colitis, Jaypirca for MCL or CCL, and Zepbound for obesity. Lilly also highlighted results from the Trailblazer-ALZ 2 study indicating a slowdown in Alzheimer's disease progression. The company delivered strong shareholder returns through share price appreciation and dividends and donated over $4 billion in medicines to charitable organizations. Lilly's 30x30 goal aims to improve healthcare for 30 million people in resource-limited settings by 2030. The company engaged with investors on topics like drug pricing, global product access, and environmental, social, and governance issues. Management proposals at the 2024 annual meeting will include eliminating the classified board structure and supermajority voting requirements in the articles of incorporation. The 2024 Annual Meeting of Shareholders will be held virtually on May 6, 2024, at 8:30 a.m. EDT.
禮來公司（Lilly）在其2023年年度股東大會通知中宣佈了一系列重大成就和戰略決策。該公司報告了監管部門對新藥的批准，包括用於潰瘍性結腸炎的Omvoh、用於MCL或CCL的Jaypirca和用於肥胖的Zepbound。禮來還強調了Trailblazer-ALZ 2研究的結果，該結果表明阿爾茨海默氏病進展放緩。該公司通過股價升值和分紅爲股東帶來了豐厚的回報，並向慈善組織捐贈了超過40億美元的藥品。禮來公司的30x30目標旨在到2030年改善資源有限環境中3000萬人的醫療保健。該公司就藥品定價、全球產品准入以及環境、社會和治理問題等話題與投資者進行了接觸。2024年年會上的管理層提案將包括取消機密董事會結構和公司章程中的絕大多數投票要求。2024年年度股東大會將在美國東部時間2024年5月6日上午8點30分虛擬舉行。
禮來公司（Lilly）在其2023年年度股東大會通知中宣佈了一系列重大成就和戰略決策。該公司報告了監管部門對新藥的批准，包括用於潰瘍性結腸炎的Omvoh、用於MCL或CCL的Jaypirca和用於肥胖的Zepbound。禮來還強調了Trailblazer-ALZ 2研究的結果，該結果表明阿爾茨海默氏病進展放緩。該公司通過股價升值和分紅爲股東帶來了豐厚的回報，並向慈善組織捐贈了超過40億美元的藥品。禮來公司的30x30目標旨在到2030年改善資源有限環境中3000萬人的醫療保健。該公司就藥品定價、全球產品准入以及環境、社會和治理問題等話題與投資者進行了接觸。2024年年會上的管理層提案將包括取消機密董事會結構和公司章程中的絕大多數投票要求。2024年年度股東大會將在美國東部時間2024年5月6日上午8點30分虛擬舉行。
有用
沒用